A novel role for autologous tumour cell vaccination in the immunotherapy of the poorly immunogenic B16-BL6 melanoma
dc.contributor.author | Geiger, J. D. | en_US |
dc.contributor.author | Wagner, Paul D. | en_US |
dc.contributor.author | Shu, S. | en_US |
dc.contributor.author | Chang, Alfred E. | en_US |
dc.date.accessioned | 2006-04-10T15:11:24Z | |
dc.date.available | 2006-04-10T15:11:24Z | |
dc.date.issued | 1992-06 | en_US |
dc.identifier.citation | Geiger, J. D., Wagner, P. D., Shu, S., Chang, A. E. (1992/06)."A novel role for autologous tumour cell vaccination in the immunotherapy of the poorly immunogenic B16-BL6 melanoma." Surgical Oncology 1(3): 199-208. <http://hdl.handle.net/2027.42/30002> | en_US |
dc.identifier.uri | http://www.sciencedirect.com/science/article/B6VN6-4BY4WCV-3/2/9ee65e64de05224416b7c5f7447e1417 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/30002 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=1341252&dopt=citation | en_US |
dc.description.abstract | The growth of immunogenic tumours stimulates the generation of tumour-sensitized, but not functional, pre-effector T cells in the draining lymph nodes. These pre-effector cells can mature into effector cells upon in-vitro stimulation with anti-CD3 and IL-2. In the current study, using a defined, poorly immunogenic tumour, B16-BL6 melanoma, the pre-effector cell response was not evident during progressive tumour growth but was elicited by vaccination with irradiated tumour cells admixed with Corynebacterium parvum. After anti-CD3/IL-2 activation, these cells were capable of mediating the regression of established pulmonary metastases. The efficacy of the vaccine depended on the doses of both tumour cells and the adjuvant. While higher numbers of tumour cells were more effective, an optimal dose (12.5 [mu]g) of C. parvum was required. The dose of irradiation was not a critical factor. After vaccination, kinetic studies revealed that the pre-effector cell response was evident 4 days later and declined after 14 days. These observations illustrate the potential role of active immunization in the cellular therapy of cancer. | en_US |
dc.format.extent | 968585 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Elsevier | en_US |
dc.title | A novel role for autologous tumour cell vaccination in the immunotherapy of the poorly immunogenic B16-BL6 melanoma | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Surgery and Anesthesiology | en_US |
dc.subject.hlbsecondlevel | Oncology and Hematology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Division of Surgical Oncology, Department of Surgery, University of Michigan, Ann Arbor, MI 48109, USA | en_US |
dc.contributor.affiliationum | Division of Surgical Oncology, Department of Surgery, University of Michigan, Ann Arbor, MI 48109, USA | en_US |
dc.contributor.affiliationum | Division of Surgical Oncology, Department of Surgery, University of Michigan, Ann Arbor, MI 48109, USA | en_US |
dc.contributor.affiliationum | Division of Surgical Oncology, Department of Surgery, University of Michigan, Ann Arbor, MI 48109, USA | en_US |
dc.identifier.pmid | 1341252 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/30002/1/0000369.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1016/0960-7404(92)90065-S | en_US |
dc.identifier.source | Surgical Oncology | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.